The value of methylated circulating tumor DNA as biomarkers in cancer diagnosis and prognosis
10.3760/cma.j.issn.1009-9158.2019.01.001
- VernacularTitle:ctDNA甲基化检测在肿瘤诊疗中的价值
- Author:
Yanjun DIAO
1
;
Juan WANG
;
Xiaoke HAO
Author Information
1. 空军军医大学第一附属医院检验科
- Keywords:
Neoplasms;
Circulating tumor DNA;
DNA methylation;
Prognosis
- From:
Chinese Journal of Laboratory Medicine
2019;42(1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Circulating tumor DNA (ctDNA) in the blood of cancer patients provides an opportunity for non-invasive sampling of tumor DNA.This "liquid biopsy"allows for detection of copy number variations,tumor-specific mutations,epigenetic changes,and can be used to guide and improve treatment throughout real-time "tracking" the course of tumor disease.Aberrant methylation of specific gene regions can be a very consistent feature of cancer,in contrast to mutations,which makes ctDNA methylation amenable to the design of widely clinical applications in early diagnosis,monitoring disease status,predicting treatment response and predicting prognosis.Therefore,ctDNA methylation detection is considered as one of the most valuable methods for cancer diagnosis and risk assessment.
